• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Offering Financial Incentives to Increase Adherence to Antipsychotic Medication: The Clinician Experience. 
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Psychiatry
    • Offering Financial Incentives to Increase Adherence to Antipsychotic Medication: The Clinician Experience.
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Psychiatry
    • Offering Financial Incentives to Increase Adherence to Antipsychotic Medication: The Clinician Experience.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Offering Financial Incentives to Increase Adherence to Antipsychotic Medication: The Clinician Experience.

    DOI
    10.1097/JCP.0000000000000276
    Metadata
    Show full item record
    Abstract
    Financial incentives for medication adherence in patients with psychotic disorders are controversial. It is not yet known whether fears expressed by clinicians are borne out in reality. We aimed to explore community mental health clinicians' experiences of the consequences of giving patients with psychotic disorders a financial incentive to take their depot medication. We implemented descriptive and thematic analyses of semistructured interviews with the clinicians of patients assigned to receive incentives within a randomized controlled trial. Fifty-nine clinicians were interviewed with regard to the effect of the incentives on 73 of the 78 patients allocated to receive incentives in the trial. Most commonly, the clinicians reported benefits for clinical management including improved adherence, contact, patient monitoring, communication, and trust (n = 52). Positive effects on symptoms, insight, or social functioning were reported for some (n = 33). Less commonly, problems for patient management were reported (n = 19) such as monetarization of the therapeutic relationship or negative consequences for the patient (n = 15) such as increased drug and alcohol use. Where requests for increased money occurred, they were rapidly resolved. It seems that, in most cases, the clinicians found that using incentives led to benefits for patient management and for patient health. However, in 33% of cases, some adverse effects were reported. It remains unclear whether certain clinical characteristics are associated with increased risk for adverse effects of financial incentives. The likelihood of benefit versus the smaller risk for adverse effects should be weighed up when deciding whether to offer incentives to individual patients.
    Authors
    Highton-Williamson, E; Barnicot, K; Kareem, T; Priebe, S
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/6750
    Collections
    • Centre for Psychiatry [748]
    Language
    ENG
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.